Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961595 | 0.76 | RAB9A (0.42) | MAPK1ALDH1A1MAPTTDP1KDM4E | |
| SCHEMBL22485142 | 0.76 | CHRNA7 (0.33) | MAPK1ALDH1A1MAPTTDP1KDM4E | |
| SCHEMBL6151146 | 0.75 | KDM4E (0.35) | MAPK1ALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL6151148 | 0.75 | KDM4E (0.35) | MAPK1ALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL22482237 | 0.74 | SMN1; SMN2 (0.32) | MAPK1ALDH1A1MAPTKDM4ECHRNA7 | |
| Hydrochloric Acid SCHEMBL7451527 | 0.73 | KDM4E (0.34) | MAPK1ALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL6962187 | 0.73 | RAB9A (0.38) | MAPK1ALDH1A1TDP1KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7451532 | 0.73 | KDM4E (0.34) | MAPK1ALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL21428536 | 0.71 | SIGMAR1 (0.30) | — | |
| SCHEMBL21428543 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2020198368-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019191189-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | MAPK1 512/4885ALDH1A1 4464/4885MAPT 237/4885 |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | MAPK1 512/4885ALDH1A1 4464/4885MAPT 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.